The Centers for Medicare & Medicaid Services (CMS) offered patients the opportunity to share their perspectives with CMS staff on a treatment critical to our community. As this year’s Inflation Reduction Act (IRA) negotiations begin, CLL Society seeks to ensure that CMS understands the importance of these treatments for both patients and physicians.
As we did last year, we focused on treatment paradigms unique to rare cancers. We highlighted the patient-focused experience, emphasizing our unique journey as CLL / SLL patients—from diagnosis to disease progression and treatment options, treatment preferences, and the ongoing unmet needs of our community. As a rare cancer community, we also urged CMS to solicit and consider patient information that reflects the whole patient, including factors such as impacts on quality of life, drug toxicity, side effect profiles, and other critical patient considerations.
Read the letter below.
